Tags

Type your tag names separated by a space and hit enter

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
Int J Chron Obstruct Pulmon Dis. 2018; 13:1545-1556.IJ

Abstract

Background

Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region.

Methods

This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other.

Results

In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV1 of 50.0%±18.6%. The ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medications used, followed by LABA/LAMA (11.3%), SABA or SAMA (7.9%), LABA (6.4%), LAMA (5.8%), and ICS (4.3%). The types of medication most commonly used in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 category were ICS/LABA (A: 32.7%; B: 19.8%; C: 25.7%; D: 28.2%) and ICS/LAMA/LABA (A: 17.3%; B: 30.2%; C: 33%; D: 41.1%). The use of long-acting bronchodilators showed the highest adherence (good or high adherence >50%) according to the TAI questionnaire.

Conclusion

COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence.

Authors+Show Affiliations

Fundación Neumológica Colombiana, Universidad del Rosario, Bogotá, Colombia.Universidad Central de Venezuela, Caracas, Venezuela.Federal University of Pelotas, Pelotas, Brazil.Federal University of Pelotas, Pelotas, Brazil.Universidad de la República, Montevideo, Uruguay.Hospital Clínico Universidad de Chile, Santiago de Chile, Chile.AstraZeneca, San José, Costa Rica.Department of Pneumology, Hospital Universitari Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study

Language

eng

PubMed ID

29785104

Citation

Casas, Alejandro, et al. "Respiratory Medication Used in COPD Patients From Seven Latin American Countries: the LASSYC Study." International Journal of Chronic Obstructive Pulmonary Disease, vol. 13, 2018, pp. 1545-1556.
Casas A, Montes de Oca M, Menezes AM, et al. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545-1556.
Casas, A., Montes de Oca, M., Menezes, A. M., Wehrmeister, F. C., Lopez Varela, M. V., Mendoza, L., Ramírez, L., & Miravitlles, M. (2018). Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. International Journal of Chronic Obstructive Pulmonary Disease, 13, 1545-1556. https://doi.org/10.2147/COPD.S154097
Casas A, et al. Respiratory Medication Used in COPD Patients From Seven Latin American Countries: the LASSYC Study. Int J Chron Obstruct Pulmon Dis. 2018;13:1545-1556. PubMed PMID: 29785104.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. AU - Casas,Alejandro, AU - Montes de Oca,Maria, AU - Menezes,Ana Mb, AU - Wehrmeister,Fernando C, AU - Lopez Varela,Maria Victorina, AU - Mendoza,Laura, AU - Ramírez,Larissa, AU - Miravitlles,Marc, Y1 - 2018/05/11/ PY - 2018/5/23/entrez PY - 2018/5/23/pubmed PY - 2018/10/10/medline KW - COPD KW - Latin America KW - adherence KW - inhaled therapy SP - 1545 EP - 1556 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 13 N2 - Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region. Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other. Results: In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV1 of 50.0%±18.6%. The ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medications used, followed by LABA/LAMA (11.3%), SABA or SAMA (7.9%), LABA (6.4%), LAMA (5.8%), and ICS (4.3%). The types of medication most commonly used in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 category were ICS/LABA (A: 32.7%; B: 19.8%; C: 25.7%; D: 28.2%) and ICS/LAMA/LABA (A: 17.3%; B: 30.2%; C: 33%; D: 41.1%). The use of long-acting bronchodilators showed the highest adherence (good or high adherence >50%) according to the TAI questionnaire. Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/29785104/Respiratory_medication_used_in_COPD_patients_from_seven_Latin_American_countries:_the_LASSYC_study_ L2 - https://dx.doi.org/10.2147/COPD.S154097 DB - PRIME DP - Unbound Medicine ER -